10-K: Karyopharm Therapeutics Faces Going Concern Uncertainty Despite XPOVIO Revenue

Sentiment:

Annual Results 19 February 2025 7:36 AM

📋All filings for Karyopharm Therapeutics INC

Karyopharm Therapeutics reports its 10-K filing, highlighting ongoing financial challenges and substantial doubt about its ability to continue as a going concern despite revenue from its drug XPOVIO.

Delay expectedTop-line data from the EC-042 Trial is expected in mid-2026 due to proposed modifications to the trial design.

Capital raiseThe company's ability to continue as a going concern is dependent on raising additional funding.The company plans to obtain additional funding through equity offerings, debt financings and refinancings, collaborations, strategic alliances and/or licensing arrangements.

Worse than expectedThe company's financial condition raises substantial doubt about its ability to continue as a going concern.The company has incurred significant operating losses since its inception and expects to continue to incur significant losses.The company's accumulated deficit as of December 31, 2024, was $1.6 billion.The company's net losses for 2024 were $76.4 million, compared to $143.1 million in 2023.

Summary

Karyopharm Therapeutics, a commercial-stage pharmaceutical company, is facing substantial doubt about its ability to continue as a going concern within one year.
This conclusion is based on the company's current business plan, capital resources, uncertainty regarding additional funding, and debt obligations, including a requirement to maintain a minimum cash balance of $25.0 million.
The company's lead asset, XPOVIO (selinexor), is approved for multiple myeloma and diffuse large B-cell lymphoma (DLBCL) in the U.S.
In May 2024, Karyopharm entered into refinancing transactions, including borrowing $100.0 million under a new senior secured term loan facility and exchanging $148.0 million of existing convertible notes for new secured convertible notes and warrants.
As of December 31, 2024, Karyopharm had an accumulated deficit of $1.6 billion and cash, cash equivalents, and investments of $108.7 million.
Net losses for 2024 were $76.4 million, compared to $143.1 million in 2023.
Total revenue for 2024 was $145.2 million, including $112.8 million from XPOVIO net product revenue and $32.4 million from license revenue.
Karyopharm is focusing on maximizing the commercial value of XPOVIO, advancing its clinical pipeline in myelofibrosis and endometrial cancer, and maintaining a well-capitalized business.
The company is conducting a Phase 3 trial (SENTRY) for selinexor in myelofibrosis, with top-line data expected in the second half of 2025.
A Phase 3 trial (EC-042) for selinexor in endometrial cancer is ongoing, with top-line data expected in mid-2026 after modifications to the trial design.
Karyopharm is also evaluating selinexor in a Phase 3 trial (EMN29) for multiple myeloma, with a reduced enrollment target and revisions to the statistical plan.
Further clinical development of the eltanexor program remains on hold to focus resources on prioritized late-stage programs.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive aspects such as revenue from XPOVIO and ongoing clinical trials, the overriding concern is the company's financial instability and the substantial doubt about its ability to continue as a going concern. This significantly overshadows the positive elements, leading to a negative sentiment.

Positives

XPOVIO is approved for multiple myeloma and DLBCL in the U.S.
Total revenue for 2024 was $145.2 million, including $112.8 million from XPOVIO net product revenue.
The company is conducting a Phase 3 trial (SENTRY) for selinexor in myelofibrosis, with top-line data expected in the second half of 2025.
A Phase 3 trial (EC-042) for selinexor in endometrial cancer is ongoing, with top-line data expected in mid-2026 after modifications to the trial design.
Karyopharm is also evaluating selinexor in a Phase 3 trial (EMN29) for multiple myeloma, with a reduced enrollment target and revisions to the statistical plan.

Negatives

Karyopharm Therapeutics faces substantial doubt about its ability to continue as a going concern.
As of December 31, 2024, Karyopharm had an accumulated deficit of $1.6 billion.
Net losses for 2024 were $76.4 million.
Further clinical development of the eltanexor program remains on hold to focus resources on prioritized late-stage programs.

Risks

The company's ability to continue as a going concern is dependent on raising additional funding.
Clinical trials may fail to demonstrate safety and effectiveness.
The company may be unable to successfully enroll patients in clinical trials.
Serious adverse side effects related to XPOVIO or product candidates may delay or prevent regulatory approval.
The company may not be successful in identifying or discovering additional potential product candidates.
The company may not be able to maintain or expand its sales, marketing, and distribution capabilities.
The company's business may be adversely affected by international risks and uncertainties.
The company may not receive regulatory approvals for its product candidates.
The company's ability to commercialize its products may be limited by the terms of regulatory approvals.
The company's failure to comply with post-approval regulatory requirements may have a material adverse effect on its business.
Changes in U.S. and international trade policies may adversely impact the company's business.
The company may not be able to satisfy its indebtedness.
The price of the company's common stock may be volatile.
Securities litigation could result in substantial costs.
The company may be unable to protect the confidentiality of its trade secrets.
Information technology system failures or security breaches may materially adversely affect the company's business and operations.

Future Outlook

Karyopharm expects net product revenue to increase in 2025 as compared to 2024 due to demand growth. License and other revenue is expected to slightly decrease in 2025 as compared to 2024 primarily due to a decrease in milestone-related revenue from our partners. Research and development expenses are expected to decrease in 2025 as compared to 2024 due primarily to full enrollment in mid-2024 of our Phase 3 multiple myeloma study and decreased headcount costs, partially offset by an increase in expenses in connection with our ongoing Phase 3 trials in myelofibrosis and endometrial cancer. Selling, general and administrative expenses are expected to slightly decrease in 2025 as compared to 2024 due to continued realization of previously implemented cost reduction initiatives. Other income (expense), net is expected to decrease in 2025 as compared to 2024 due to the $44.7 million gain on extinguishment of debt being a one-time, non-recurring item. We also expect increased interest expense in 2025 as compared to 2024 on the Term Loan and the 2029 Notes, as both of these instruments were issued in May 2024, and 2025 will include a full year of interest expense on these instruments.

Industry Context

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Karyopharm faces competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that Karyopharm successfully develops and commercializes will compete with existing therapies and new therapies that may become available in the future.

Comparison to Industry Standards

The document does not provide enough information to make a detailed comparison to industry standards.
To perform a comparison, specific benchmarks for comparable companies, projects, and results would be needed.
Without this information, it is difficult to assess whether Karyopharm's results are in line with or deviate from industry norms.

Stakeholder Impact

Shareholders face the risk of losing their investment if the company is unable to continue as a going concern.
Employees may be affected by potential layoffs or reduced compensation if the company is forced to curtail operations.
Patients may experience disruptions in access to XPOVIO or other potential treatments if the company is unable to continue its research and development programs.
Suppliers and creditors may face financial losses if the company is unable to meet its obligations.

Next Steps

Complete enrollment of the SENTRY Trial in the first half of 2025.
Report top-line data from the SENTRY Trial in the second half of 2025.
Submit an amendment to the EC-042 Trial protocol to the FDA and other relevant global regulatory authorities.
Continue to enroll patients in the EC-042 Trial.
Announce selection of up to 15 additional drugs covered by Part D for the second cycle of negotiations by February 1, 2025.

Key Dates

Date	Description
2018-05	Original license agreement with Antengene Therapeutics Limited.
2019-07	Initial U.S. FDA approval of XPOVIO.
2019-09	Entered into Revenue Interest Financing Agreement with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P.
2020-06	FDA approved XPOVIO under accelerated approval as a single-agent oral treatment of adult patients with relapsed or refractory DLBCL.
2020-12	FDA approval of XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
2021-06	Amended the Revenue Interest Financing Agreement with HealthCare Royalty Partners III, L.P. and HealthCare Royalty Partners IV, L.P.
2021-12	Entered into a license agreement with the Menarini Group.
2022-05	FDA granted selinexor Orphan Drug Designation for the treatment of myelofibrosis.
2023-03	Amended the Original Menarini Agreement to expand the Menarini Territory.
2023-07	Received Fast Track Designation from the FDA for selinexor for the treatment of patients with myelofibrosis.
2024-05	Entered into a series of transactions (the Refinancing Transactions) to limit aggregate indebtedness, extend the maturity of certain indebtedness and provide additional working capital.
2025-06	Expect to complete enrollment of the SENTRY Trial.
2025-Q4	Expect existing cash, cash equivalents and investments will be sufficient to fund current operating plans and debt obligation requirements.
2025-H2	Expect to report top-line data from the SENTRY Trial.
2026-Mid	Expect top-line data from the EC-042 Trial.

Keywords

Karyopharm Therapeutics, XPOVIO, selinexor, myelofibrosis, endometrial cancer, multiple myeloma, DLBCL, clinical trials, regulatory approval, financial condition, going concern, revenue, net loss, debt, refinancing, Orphan Drug Designation, SINE compounds, FDA, EMEA

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.